Trial Profile
A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Fedratinib (Primary)
- Indications Anaemia; Myelofibrosis
- Focus Registrational; Therapeutic Use
- Acronyms FREEDOM
- Sponsors Celgene Corporation
- 28 Nov 2023 Status changed from active, no longer recruiting to completed.
- 15 Jun 2023 Results exploring potential mechanisms of FEDR efficacy after RUX exposure using clinical and preclinical data presented at the 28th Congress of the European Haematology Association
- 13 Dec 2022 Results of a biomarker analysis assessing changes to cytokine profile in ruxolitinib exposed myelofibrosis patients presented at the 64th American Society of Hematology Annual Meeting and Exposition